Leukemia
Vyxeos (Daunorubicin and Cytarabine) liposome for injection
- A Review that summarizes the robust data on Vyxeos (CPX-351) from all real-world experience with the medication can be found in the following article by Lemoli R. et al.
- More details on Vyxeos you can find in the 301 study by JE Lancet et al. which examined the efficacy and safety of Vyxeos (CPX-351) vs the standard of care (7+3 protocol) in newly diagnosed patients with secondary AML (t-AML or AML-MRC).
- Additional information on the 5-year follow up on the results of the 301 study could be found in a paper by JE Lancet et al. that was published in 2021.
- To the official website please click here
Blincyto (Blinatumomab)
VOD
Defitelio (Defibrotide sodium)
- To the official website please click here
- For more details regarding Defitelio, you can find in the pediatrics VOD/SOS Diagnosis and severity criteria .by Salim Corbaciogluetal
- For more details regarding Defitelio, you can find in the adults VOD/SOS Diagnosis and severity criteria by Mohamad Mohty et al
Lymphoma
Brukinsa (Zanubrutinib)
- For more details regarding Zanubrutinib, you can find in the SEQUOIA phase III study by Prof. Constantine Tam et al, which examined the effectiveness and safety of Zanubrutinib in CLL/SLL patients in the first line of treatment.
- For more details regarding Zanubrutinib, you can find in the ALPINE phase III study by Prof. Peter Hillmen et al, which examined the effectiveness and safety of Zanubrutinib compared to Ibrutinib in CLL/SLL patients with relapsed or refractory disease.
- To the official website please click here
- To refer your patients to Brukinsa support program
Poteligeo (Mogamulizumab)
- Poteligeo (Mogamulizumab)
For more details regarding Poteligeo, you can find in the MAVORIC phase III study by Prof. Youn H Kim et al, which examined the effectiveness and safety of Mogamulizumab in MF and SS CTCL patients who have received at least one previous systemic therapy - To the official website please click here
ITP
Nplate (Romiplostim)
Tavalisse (Fostamatinib)
Multiple Myeloma
Neuroblastoma
The resources provide links that may contain off-label indications. Please refer to the PI and indications, as approved by the Israeli MOH Privacy statement. The resources provide links to third-party sites where more information can be found, and this does not indicate collaboration or sponsorship with the author and/or the licensee. Unless otherwise indicated, all information such as text, graphics, logos and images, is copyrighted and you will need to obtain permission directly from the copyright holder.